| Baseline | One year post-PEA | p-value |
---|---|---|---|
Patients, n | 37 | Â | |
Male/female | 20/17 | Â | |
Age (y) | 61 ± 12 |  | |
BMI (kg/m2) | 27.9 ± 5.8 |  | |
WHO functional class, (%) | Â | b | 0.7 |
 I | none | 29.6 |  |
 II | 27 | 48.1 |  |
 III | 62.2 | 22.2 |  |
 IV | 10.8 | None |  |
6MWT | Â | Â | Â |
 6MWD (m) | 404.7 ± 148.4 | 453.4 ± 126.8 | 0.1 |
 Rest SpO2 (%) | 93.9 ± 2.7 | 95.6 ± 2.9 | 0.043 |
 Peak SpO2 (%) | 88.8 ± 5.6 | 92.2 ± 4.5 | 0.003 |
 Δ SpO2 (%) | −5.1 ± 4.4 | −3.5 ± 4.1 | 0.15 |
 Rest HR (beatsbmin-1) | 83.8 ± 14.4 | 83.5 ± 13.9 | 0.98 |
 Peak HR (beatsbmin-1) | 117.1 ± 18.8 | 107.8 ± 17.1 | 0.041 |
 Δ HR (beatsbmin-1) | 32.6 ± 14.7 | 24.3 ± 12.9 | 0.038 |
 HRR (%) | 45.1 ± 20.6 | 33.4 ± 16.7 | 0.022 |
 Δ Borg | 4.4 ± 2.2 | 3.1 ± 2.4 | 0.006 |
 Supplemental Oxygen (n, %) | 9 (24.3) | 3 (8.1)b | 0.33 |
Lung function | Â | Â | Â |
 FEV1 (% pred.) | 88.7 ± 13.8 | 88.2 ± 12.5 | 0.76 |
 FEV1/FVC (% pred.) | 96 ± 10.3 | 90.6 ± 12.1 | 0.05 |
 TLC (% pred.) | 99 ± 13.5 | 104.8 ± 16.8 | 0.11 |
 VC (% pred.) | 91.6 ± 13.7 | 94 ± 12.7 | 0.34 |
RHC | Â | Â | |
 mPAP (mm Hg) | 43.2 ± 8.7 | 28.9 ± 10.1 | 0.001 |
 RAP (mm Hg) | 5.9 ± 4.1 | 7.2 ± 4.3 | 0.15 |
 PVR (dynebs/cm5) | 605.5 ± 228.7 | 328.1 ± 241.4 | 0.001 |
 CI (l/min/m2) | 2.4 ± 0.5 | 2.7 ± 1.3 | 0.048 |
 PAWP (mm Hg) | 9.5 ± 4.6 | 10.6 ± 4.5 | 0.19 |
Echocardiography | Â | Â | |
 TAPSE (mm) | 17.2 ± 4.3 | 17.5 ± 3.2 | 0.62 |
 PASP (mm Hg) | 69.8 ± 25.1 | 56.8 ± 23.7 | 0.041 |
CPETc | Â | Â | Â |
 Peak VO2 (ml/min/kg) | 12.3 ± 3.4 | 14.2 ± 4.2 | 0.33 |
 Rest VD/VT | 35.2 ± 7.6 | 32 ± 5.8 | 0.77 |
 Peak VD/VT | 39.5 ± 8.7 | 35 ± 11.9 | 0.6 |
 Rest VD, L | 0.35 ± 0.17 | 0.29 ± 0.11 | 0.39 |
 Peak VD, L | 0.65 ± 0.25 | 0.72 ± 0.21 | 0.55 |
 Rest SpO2 (%) | 94.2 ± 1.7 | 95.1 ± 1.4 | 0.10 |
 Peak SpO2 (%) | 89.3 ± 1.4 | 90.7 ± 4.8 | 0.86 |
 Δ SpO2 (%) | −4.9 ± 5.8 | −4.4 ± 4.3 | 0.69 |
 Rest HR (beatsbmin-1) | 72.8 ± 12.2 | 81.2 ± 11.2 | 0.15 |
 Peak HR (beatsbmin-1) | 120.7 ± 21.3 | 122.9 ± 19.6 | 0.25 |
 Δ HR (beatsbmin-1) | 47.9 ± 19.4 | 41.7 ± 16.3 | 0.72 |
 HRR (%) | 54.7 ± 21.1 | 53.7 ± 20.2 | 0.92 |
Co-morbidities, n (%) | Â | Â | |
 Hypertension | 24 (64.9) | Unchanged |  |
 Coronary heart disease | 4 (10.8) | Unchanged |  |
 Renal insuffiency | 4 (10.8) | Unchanged |  |
Jamieson-Type, % | Â | Â | |
 I | 31 |  | |
 II | 31 |  | |
 III | 38 |  | |
Laboratory | Â | Â | |
 NT-proBNP (pg/ml) | 488.2 [1004] | 245.0 [422]a | 0.006 |